Curis, Inc. (CRIS) to Release Quarterly Earnings on Wednesday
Curis, Inc. (NASDAQ:CRIS) is scheduled to announce its earnings results before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.
Curis (NASDAQ:CRIS) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The business had revenue of $2.10 million for the quarter, compared to analysts’ expectations of $2.08 million. Curis had a negative return on equity of 236.43% and a negative net margin of 836.18%. The business’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.09) earnings per share. On average, analysts expect Curis to post $-0.4 EPS for the current fiscal year and $-0.4 EPS for the next fiscal year.
Curis, Inc. (NASDAQ CRIS) opened at 1.65 on Wednesday. The stock’s 50 day moving average price is $1.71 and its 200-day moving average price is $1.90. Curis, Inc. has a 12-month low of $1.47 and a 12-month high of $3.72. The stock’s market capitalization is $237.40 million.
An institutional investor recently raised its position in Curis stock. The Manufacturers Life Insurance Company increased its holdings in Curis, Inc. (NASDAQ:CRIS) by 8.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,023 shares of the biotechnology company’s stock after purchasing an additional 8,102 shares during the period. The Manufacturers Life Insurance Company owned 0.07% of Curis worth $190,000 as of its most recent SEC filing. Institutional investors and hedge funds own 44.72% of the company’s stock.
A number of brokerages have recently commented on CRIS. ValuEngine downgraded Curis from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. BidaskClub downgraded Curis from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research raised Curis from a “sell” rating to a “hold” rating in a research report on Monday, October 16th. Finally, Guggenheim began coverage on Curis in a research report on Monday. They issued a “buy” rating and a $7.00 price objective for the company. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Curis has an average rating of “Hold” and a consensus target price of $6.50.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.